BioSpace News Archive

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2020 after the U.S.

Collaboration aims to enable discovery of first-in-class therapeutic candidates

CytoSorbents Corporation announced that the Data Monitoring Committee of the REFRESH 2-AKI trial has completed a comprehensive favorable review of safety data from the study with a positive recommendation to resume the trial.

Company, seeing early success, will advance preparations for Phase 2a clinical trial in opioid addiction

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020 . The press release will be followed by a conference call at 8:00

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to discuss

Recordati Rare Diseases Inc. announces today that Lancet Diabetes & Endocrinology has published results from the Phase III LINC-3 pivotal study of ISTURISA, recently approved for the treatment of Cushing’s disease in adults

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 (HER2) mutation or an epidermal g

Hutchison China MediTech Limited announced that the China National Medical Products Administration has granted Priority Review status to the New Drug Application for savolitinib for the treatment of non-small cell lung cancer with MET Exon 14 skipping mutations.

PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland Europe